NO175216B - - Google Patents

Info

Publication number: NO175216B
Authority: NO; Norway
Prior art keywords: amino acid; fragment; plasminogen activator; mutant; chain
Prior art date: 1985-04-22

Application number

NO861559A

Other languages

English (en)

Norwegian (no)

Other versions

NO861559L (no

NO175216C (no

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-22

Filing date

1986-04-21

Publication date

1994-06-06

1986-04-21 Application filed filed Critical

1986-10-23 Publication of NO861559L publication Critical patent/NO861559L/no

1994-06-06 Publication of NO175216B publication Critical patent/NO175216B/no

1994-09-14 Publication of NO175216C publication Critical patent/NO175216C/no

Links

108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 179
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims abstract description 173
229960000187 tissue plasminogen activator Drugs 0.000 claims abstract description 170
150000001413 amino acids Chemical class 0.000 claims abstract description 44
239000013604 expression vector Substances 0.000 claims abstract description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
238000003776 cleavage reaction Methods 0.000 claims abstract description 14
230000007017 scission Effects 0.000 claims abstract description 14
238000004113 cell culture Methods 0.000 claims abstract description 9
230000002255 enzymatic effect Effects 0.000 claims abstract description 4
235000001014 amino acid Nutrition 0.000 claims description 37
229940024606 amino acid Drugs 0.000 claims description 32
210000004027 cell Anatomy 0.000 claims description 32
238000000034 method Methods 0.000 claims description 26
108020004414 DNA Proteins 0.000 claims description 20
239000004475 Arginine Substances 0.000 claims description 9
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
229960000310 isoleucine Drugs 0.000 claims description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
239000004471 Glycine Substances 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
235000013922 glutamic acid Nutrition 0.000 claims 1
239000004220 glutamic acid Substances 0.000 claims 1
241000588724 Escherichia coli Species 0.000 abstract description 30
239000013598 vector Substances 0.000 abstract description 21
108091034117 Oligonucleotide Proteins 0.000 abstract description 8
238000002741 site-directed mutagenesis Methods 0.000 abstract description 8
241000699802 Cricetulus griseus Species 0.000 abstract description 3
230000010076 replication Effects 0.000 abstract description 3
241000724220 Phage M13mp8 Species 0.000 abstract description 2
210000001672 ovary Anatomy 0.000 abstract description 2
244000005700 microbiome Species 0.000 abstract 1
239000012634 fragment Substances 0.000 description 62
239000013612 plasmid Substances 0.000 description 52
230000000694 effects Effects 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
108010073385 Fibrin Proteins 0.000 description 17
102000009123 Fibrin Human genes 0.000 description 17
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 17
238000003556 assay Methods 0.000 description 17
229950003499 fibrin Drugs 0.000 description 17
102000001938 Plasminogen Activators Human genes 0.000 description 15
108010001014 Plasminogen Activators Proteins 0.000 description 15
229940012952 fibrinogen Drugs 0.000 description 15
229940127126 plasminogen activator Drugs 0.000 description 15
102000008946 Fibrinogen Human genes 0.000 description 14
108010049003 Fibrinogen Proteins 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
102000047823 human PLAT Human genes 0.000 description 13
239000000523 sample Substances 0.000 description 12
102000013566 Plasminogen Human genes 0.000 description 11
108010051456 Plasminogen Proteins 0.000 description 11
239000004098 Tetracycline Substances 0.000 description 11
230000009089 cytolysis Effects 0.000 description 11
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
229960002180 tetracycline Drugs 0.000 description 11
229930101283 tetracycline Natural products 0.000 description 11
235000019364 tetracycline Nutrition 0.000 description 11
150000003522 tetracyclines Chemical class 0.000 description 11
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000000872 buffer Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
101150006320 trpR gene Proteins 0.000 description 9
102000035195 Peptidases Human genes 0.000 description 8
108091005804 Peptidases Proteins 0.000 description 8
239000004365 Protease Substances 0.000 description 8
108091036066 Three prime untranslated region Proteins 0.000 description 8
230000029087 digestion Effects 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
108020004705 Codon Proteins 0.000 description 7
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 7
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 7
238000010276 construction Methods 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000035772 mutation Effects 0.000 description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
239000006166 lysate Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
102000004594 DNA Polymerase I Human genes 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 5
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
238000012360 testing method Methods 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
108090000317 Chymotrypsin Proteins 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
238000007792 addition Methods 0.000 description 4
238000000376 autoradiography Methods 0.000 description 4
229960002376 chymotrypsin Drugs 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
101150077341 fhuA gene Proteins 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
235000011008 sodium phosphates Nutrition 0.000 description 4
239000000243 solution Substances 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 3
108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108050004197 Trp repressor Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000001802 infusion Methods 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000001810 trypsinlike Effects 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000702191 Escherichia virus P1 Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
229940106780 human fibrinogen Drugs 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
241001522878 Escherichia coli B Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102100027612 Kallikrein-11 Human genes 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
101710152431 Trypsin-like protease Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000007605 air drying Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
235000012434 pretzels Nutrition 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO861559A 1985-04-22 1986-04-21 Fremgangsmåte for fremstilling av human vevs-plasminogen-aktivator, DNA sekvens, replikerbar ekspresjonsvektor og cellekultur NO175216C (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72546885A	1985-04-22	1985-04-22
US84669786A	1986-04-01	1986-04-01

Publications (3)

Publication Number	Publication Date
NO861559L NO861559L (no)	1986-10-23
NO175216B true NO175216B (de)	1994-06-06
NO175216C NO175216C (no)	1994-09-14

Family

ID=27111150

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO861559A NO175216C (no)	1985-04-22	1986-04-21	Fremgangsmåte for fremstilling av human vevs-plasminogen-aktivator, DNA sekvens, replikerbar ekspresjonsvektor og cellekultur

Country Status (21)

Country	Link
US (1)	US5147643A (de)
EP (1)	EP0199574B1 (de)
JP (2)	JPH0740940B2 (de)
AT (1)	ATE68825T1 (de)
AU (1)	AU596356B2 (de)
CA (1)	CA1341580C (de)
DD (1)	DD258026A5 (de)
DE (2)	DE3613390C2 (de)
DK (1)	DK175380B1 (de)
ES (2)	ES8802184A1 (de)
FI (1)	FI98930C (de)
FR (1)	FR2581652B1 (de)
GB (1)	GB2173804B (de)
GR (1)	GR861037B (de)
HU (1)	HU206520B (de)
IE (1)	IE58574B1 (de)
IL (1)	IL78571A (de)
MY (1)	MY102550A (de)
NO (1)	NO175216C (de)
NZ (1)	NZ215920A (de)
PT (1)	PT82429B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614190A (en) *	1988-09-02	1997-03-25	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58149871A (ja) *	1982-02-27	1983-09-06	本田技研工業株式会社	二，三輪車の盗難防止装置
JPS6087751A (ja) *	1983-10-20	1985-05-17	House Food Ind Co Ltd	レトルト豆腐の製造法
EP0201153A3 (de) *	1985-02-09	1987-10-07	Beecham Group Plc	Modifiziertes Enzym und Verfahren zu dessen Herstellung
WO1986005096A1 (en) *	1985-03-06	1986-09-12	Survival Technology, Inc.	Protein absorption enhancing agents
US5756093A (en) *	1985-04-22	1998-05-26	Genentech, Inc.	Tissue plasminogen activator variants
US5736134A (en) *	1985-04-22	1998-04-07	Genentech, In.C	Tissue plasminogen activator variants
DK175380B1 (da) *	1985-04-22	2004-09-20	Genentech Inc	Mutant af human vævsplasminogenaktivator, DNA-sekvens som koder herfor, replicerbar udtrykkelsesvektor til at udtrykke denne DNA-sekvens, mikroorganisme transformeret med denne vektor, cellekulturer transformeret med denne....
WO1993012225A1 (en) *	1991-12-16	1993-06-24	Genentech, Inc.	Novel tissue plasminogen activator variants
US4959318A (en) *	1985-06-27	1990-09-25	Zymogenetics, Inc.	Expression of protein C
US4777043A (en) *	1985-12-17	1988-10-11	Genentech, Inc.	Stabilized human tissue plasminogen activator compositions
AU605124B2 (en) *	1985-12-23	1991-01-10	Behringwerke Aktiengesellschaft	Novel peptide plasminogen activators
DK43387A (da) *	1986-01-29	1987-07-30	Beecham Group Plc	Fibrinolytisk enzym
US5258298A (en) *	1986-01-31	1993-11-02	Genetics Institute, Inc.	Deletion and glycosylation mutant of human tissue plasminogen activator
US5071972A (en) *	1986-01-31	1991-12-10	Genetics Institute, Inc.	DNA sequences encoding novel thrombolytic proteins
US5837518A (en) *	1986-01-31	1998-11-17	Genetics Institute, Inc.	Thrombolytic proteins
JP2527454B2 (ja) *	1986-01-31	1996-08-21	ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド	新しい血栓溶解タンパク質
IE81073B1 (en) *	1986-03-18	2000-01-12	Genentech Inc	Modified human tissue-type plasminogen activator and its preparation
US5589361A (en) *	1986-03-18	1996-12-31	Genentech, Inc.	Human tissue-type plasminogen activator variant
PT84589B (en) *	1986-04-02	1989-05-09	Beecham Group Plc	Process for preparing a fibrinolytic enzyme
PT84588B (en) *	1986-04-02	1989-05-09	Beecham Group Plc	Process for preparing a fibrinolytic enzyme
US5169763A (en) *	1986-04-08	1992-12-08	Transgene S.A., Institut Pasteur	Viral vector coding glycoprotein of HIV-1
GB8701811D0 (en) *	1987-01-28	1987-03-04	Beecham Group Plc	Compounds
MY103358A (en) *	1987-04-15	1993-06-30	Novartis Ag	Process for the production of protiens.
US5200340A (en) *	1987-05-22	1993-04-06	Zymogenetics, Inc.	Thrombin-activated tissue plasminogen activators
EP0292009A1 (de) *	1987-05-22	1988-11-23	Zymogenetics, Inc.	Fibrinolytische Proteine
ZA883958B (en) *	1987-06-04	1989-07-26	Zymogenetics Inc	Mutant t-pa with ringle replacement
NO179874C (no) *	1987-06-04	1997-01-02	Zymogenetics Inc	Fremgangsmåte for fremstilling av en t-PA-analog, DNA-sekvens som koder for t-PA-analogen, samt ekspresjonsvektor omfattende DNA-sekvensen og vertcelle omfattende denne
JPH02504102A (ja) *	1987-06-30	1990-11-29	ジェネンテク，インコーポレイテッド	血管障害治療のための改良法
US5302390A (en) *	1987-07-01	1994-04-12	Beecham Group Plc	Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
IL87276A (en) *	1987-08-03	1995-07-31	Fujisawa Pharmaceutical Co	Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
JP2708749B2 (ja) *	1987-08-10	1998-02-04	エーザイ株式会社	修飾型ｔＰＡ含有注射用組成物
US4963357A (en) *	1987-10-09	1990-10-16	Monsanto Company	Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
US5244676A (en) *	1987-10-09	1993-09-14	Monsanto Company	Modified tissue plasminogen activator with modified glycosylation site
US5037752A (en) *	1987-10-09	1991-08-06	Monsanto Company	Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277
EP0312346B1 (de) *	1987-10-16	1994-08-17	Genencor International, Inc.	Sequenzspezifische saure E.coli-Protease
KR970005046B1 (ko) *	1987-10-29	1997-04-11	야마노우찌 세이야꾸 가부시끼가이샤	개량형 조직 플라스미노겐 활성화 인자
US5504001A (en) *	1987-11-25	1996-04-02	Zymogenetics, Inc.	Hybrid plasminogen activator
US5094953A (en) *	1988-03-21	1992-03-10	Genentech, Inc.	Human tissue plasminogen activator variants
CA1320162C (en) *	1988-08-11	1993-07-13	California Biotechnology Inc.	Method for stabilizing heterologous protein expression and vectors for use therein
US5714145A (en) *	1988-09-02	1998-02-03	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
US5108901A (en) *	1988-09-02	1992-04-28	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
US5258180A (en) *	1988-09-02	1993-11-02	Genetech, Inc.	Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5087572A (en) *	1989-12-01	1992-02-11	Genentech, Inc.	Dna encoding human plasminogen modified at the cleavage site
US5190756A (en) *	1989-12-01	1993-03-02	Genentech, Inc.	Methods and materials for expression of human plasminogen variant
DE3942142A1 (de) *	1989-12-20	1991-06-27	Boehringer Mannheim Gmbh	Stabilisierung von glykosyliertem t-pa
ATE145669T1 (de) *	1991-12-16	1996-12-15	Genentech Inc	T-pa substitutionsvarianten mit verbesserter fibrinspezifität
DK0643772T3 (da) *	1992-06-03	1998-02-02	Genentech Inc	Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
GB2298821A (en) *	1995-03-15	1996-09-18	Prestek Ltd	A ribbon winding mechanism
DE69719265T2 (de) *	1996-09-06	2003-12-04	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto	Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
CN1244894A (zh) *	1996-11-12	2000-02-16	斯克里普斯研究所	组织型纤溶酶原活化剂(t－PA)变体:组合物及使用方法
US6706504B1 (en)	1996-11-12	2004-03-16	The Scripps Research Institute	Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
US5837688A (en) *	1996-11-27	1998-11-17	Gelfand; Mathew I.	Use of thrombolytic reagents for prevention of vascular disease
WO2002020802A1 (en) *	2000-09-04	2002-03-14	Hunan Royal Biotech	A cell line expressing mutant human tissue-type plasminogen activator, constructing strategy and method of expressed protein preparation
US7597895B2 (en) *	2001-02-20	2009-10-06	The Governing Council Of The University Of Toronto	Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en)	2001-02-20	2009-07-07	Kane Biotech, Inc.	Signal peptides, nucleic acid molecules and methods for treatment of caries

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT198302091A (es) *	1982-05-05	1984-10-25		Activador de plasminogeno de tejido humano a),b),c).
IL68561A (en) *	1982-05-05	1991-01-31	Genentech Inc	Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
IL90047A (en) *	1982-10-19	1992-12-01	Cetus Oncology Corp	Cysteine-depleted biologically active muteins other than interferon - '
US4753879A (en) *	1984-08-27	1988-06-28	Biogen N.V.	Modified tissue plasminogen activators
EP0201153A3 (de) *	1985-02-09	1987-10-07	Beecham Group Plc	Modifiziertes Enzym und Verfahren zu dessen Herstellung
DK175380B1 (da) *	1985-04-22	2004-09-20	Genentech Inc	Mutant af human vævsplasminogenaktivator, DNA-sekvens som koder herfor, replicerbar udtrykkelsesvektor til at udtrykke denne DNA-sekvens, mikroorganisme transformeret med denne vektor, cellekulturer transformeret med denne....
DK43387A (da) *	1986-01-29	1987-07-30	Beecham Group Plc	Fibrinolytisk enzym
JP2527454B2 (ja) *	1986-01-31	1996-08-21	ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド	新しい血栓溶解タンパク質

1986
- 1986-04-21 DK DK198601812A patent/DK175380B1/da not_active IP Right Cessation
- 1986-04-21 DE DE3613390A patent/DE3613390C2/de not_active Expired - Lifetime
- 1986-04-21 AU AU56416/86A patent/AU596356B2/en not_active Expired
- 1986-04-21 NO NO861559A patent/NO175216C/no unknown
- 1986-04-21 FI FI861673A patent/FI98930C/fi not_active IP Right Cessation
- 1986-04-21 HU HU861676A patent/HU206520B/hu unknown
- 1986-04-21 AT AT86302980T patent/ATE68825T1/de not_active IP Right Cessation
- 1986-04-21 DD DD28944386A patent/DD258026A5/de unknown
- 1986-04-21 FR FR868605756A patent/FR2581652B1/fr not_active Expired
- 1986-04-21 DE DE8686302980T patent/DE3682104D1/de not_active Expired - Lifetime
- 1986-04-21 PT PT82429A patent/PT82429B/pt unknown
- 1986-04-21 GR GR861037A patent/GR861037B/el unknown
- 1986-04-21 EP EP86302980A patent/EP0199574B1/de not_active Expired - Lifetime
- 1986-04-21 IE IE105586A patent/IE58574B1/en not_active IP Right Cessation
- 1986-04-21 GB GB8609683A patent/GB2173804B/en not_active Expired
- 1986-04-21 IL IL78571A patent/IL78571A/xx not_active IP Right Cessation
- 1986-04-22 NZ NZ215920A patent/NZ215920A/xx unknown
- 1986-04-22 ES ES554251A patent/ES8802184A1/es not_active Expired
- 1986-04-22 JP JP61094382A patent/JPH0740940B2/ja not_active Expired - Lifetime
- 1986-04-22 CA CA000507294A patent/CA1341580C/en not_active Expired - Fee Related
1987
- 1987-09-21 MY MYPI87001800A patent/MY102550A/en unknown
1988
- 1988-01-15 ES ES557800A patent/ES9000011A1/es not_active Expired
1991
- 1991-08-05 US US07/741,120 patent/US5147643A/en not_active Expired - Lifetime
1994
- 1994-02-16 JP JP6019382A patent/JP2529816B2/ja not_active Expired - Lifetime

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614190A (en) *	1988-09-02	1997-03-25	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
US5616486A (en) *	1988-09-02	1997-04-01	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
US5728567A (en) *	1988-09-02	1998-03-17	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
US5770426A (en) *	1988-09-02	1998-06-23	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties

Also Published As

Publication number	Publication date
US5147643A (en)	1992-09-15
ES9000011A1 (es)	1990-03-01
GB2173804A (en)	1986-10-22
HUT40703A (en)	1987-01-28
AU5641686A (en)	1986-10-30
IL78571A0 (en)	1986-08-31
GR861037B (en)	1986-07-16
PT82429B (pt)	1988-03-03
FR2581652A1 (fr)	1986-11-14
IE58574B1 (en)	1993-10-06
FI861673A0 (fi)	1986-04-21
ATE68825T1 (de)	1991-11-15
DK181286D0 (da)	1986-04-21
NO861559L (no)	1986-10-23
AU596356B2 (en)	1990-05-03
DE3613390A1 (de)	1986-10-30
ES8802184A1 (es)	1988-04-16
FI861673L (fi)	1986-10-23
EP0199574B1 (de)	1991-10-23
FR2581652B1 (fr)	1989-12-22
DE3613390C2 (de)	2001-10-11
JP2529816B2 (ja)	1996-09-04
DK175380B1 (da)	2004-09-20
FI98930B (fi)	1997-05-30
EP0199574A3 (en)	1987-08-05
DE3682104D1 (de)	1991-11-28
DK181286A (da)	1986-10-23
HU206520B (en)	1992-11-30
JPS6224A (ja)	1987-01-06
DD258026A5 (de)	1988-07-06
PT82429A (en)	1986-05-01
GB8609683D0 (en)	1986-05-29
GB2173804B (en)	1989-07-05
NZ215920A (en)	1989-07-27
JPH0740940B2 (ja)	1995-05-10
CA1341580C (en)	2008-09-30
JPH06277071A (ja)	1994-10-04
IE861055L (en)	1986-10-22
ES554251A0 (es)	1988-04-16
FI98930C (fi)	1997-09-10
IL78571A (en)	1991-06-30
MY102550A (en)	1992-07-31
NO175216C (no)	1994-09-14
EP0199574A2 (de)	1986-10-29
ES557800A0 (es)	1990-03-01

Publication	Publication Date	Title
NO175216B (de)	1994-06-06
EP0620279B1 (de)	2003-02-05	Herstellung von funktionellen, menschlichen Urokinaseproteinen
US4935237A (en)	1990-06-19	Processes for the preparation of t-PA mutants
PL152438B1 (en)	1990-12-31	Method of obtaining of the human tissular plasminogen activator
JP2605155B2 (ja)	1997-04-30	新規なヒト組織プラスミノーゲンアクチベーター変異体および方法
HU200615B (en)	1990-07-28	Methods of preparing tissue plasiminogen activator derivative composition
NO310778B1 (no)	2001-08-27	Fremgangsmåte for fremstilling av vevsplasminogen-aktivator med zymogeniske eller fibrinspesifikke egenskaper
US5073494A (en)	1991-12-17	Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
US5112755A (en)	1992-05-12	Preparation of functional human urokinase proteins
WO1988005081A2 (en)	1988-07-14	Novel plasminogen activator
US5714372A (en)	1998-02-03	Tissue plasminogen activator variants
EP0365597B2 (de)	2005-02-09	Verfahren zur behandlung von gefässkrankheiten
US5037646A (en)	1991-08-06	Processes for the treatment of vascular disease
GB2246133A (en)	1992-01-22	Amidated human pro-urokinase enzymes and their precursors
BG60507B2 (bg)	1995-06-30	Човешки тъканен плазминогенен активатор
AU2079588A (en)	1989-01-30	Improved processes for the treatment of vascular disease
GB2121050A (en)	1983-12-14	Preparation of functional human urokinase proteins
HU202280B (en)	1991-02-28	Process for producing functional human urokinase proteins
HU210541A9 (hu)	1995-05-29	Zimogén- vagy fibrin-specifikus tulajdonságú, a 296-299 aminosav-tartományban helyettesített szöveti plazminogén aktivátor, ezt kódoló DNS-molekulák, vektorok és gazdasejtek